Beyond overall survival: Time to agree on the value of alternative oncology endpoints?
Clarivate
MAY 21, 2024
The resulting complexity feeds a vicious cycle: a lack of standardized methodologies for evidence generation leads to insufficient evidence to quantify the long-term benefits of non-OS endpoints, deterring HTA bodies from giving due consideration to these outcomes in decision making [6]. Oncologist, 2010. Am J Cancer Res, 2021.
52 
Let's personalize your content